Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.33 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.33 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960806 | 0.84 | PNP (0.38) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL26948743 | 0.84 | ADORA2B (0.42) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL874734 | 0.82 | ADORA2A (0.45) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL3671337 | 0.79 | PNP (0.37) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL6464905 | 0.79 | PNP (0.35) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL667794 | 0.79 | PDE4A (0.49) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL5667528 | 0.79 | ADORA2B (0.47) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL6265529 | 0.79 | PDE4A (0.34) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5048171 | 0.78 | PNP (0.39) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5503490 | 0.78 | ADORA2A (0.49) | ADORA2BADORA2AADORA3PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363172-A1 | 5'-CAP-TRINUCLEOTIDE- OR HIGHER OLIGONUCLEOTIDE COMPOUNDS AND THEIR USE IN STABILIZING RNA, EXPRESSING PROTEINS IN THERAPY | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2021-11-25 | — | — | US | claimed |
| EP-3765477-A1 | 5'-CAP-TRINUCLEOTIDE- OR HIGHER OLIGONUCLEOTIDE COMPOUNDS AND THEIR USES IN STABILIZING RNA, EXPRESSING PROTEINS AND IN THERAPY | BioNTech RNA Pharmaceuticals GmbH (DE) | 2021-01-20 | — | — | EP | claimed |
| CN-112119084-A | 5' -cap trinucleotide or higher oligonucleotide compounds and their use in RNA stabilization, protein expression and therapy | 生物技术RNA制药有限公司 | 2020-12-22 | — | — | CN | claimed |
| WO-2019175356-A1 | 5'-CAP-TRINUCLEOTIDE- OR HIGHER OLIGONUCLEOTIDE COMPOUNDS AND THEIR USES IN STABILIZING RNA, EXPRESSING PROTEINS AND IN THERAPY | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2019-09-19 | — | — | WO | claimed |
| US-9909169-B2 | Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2018-03-06 | — | — | US | claimed |
| EP-3234180-A1 | ALLELE-SPECIFIC AMPLIFICATION OF NUCLEIC ACIDS USING BLOCKING OLIGONUCLEOTIDES FOR WILD TYPE SUPPRESSION | Roche Diagnostics GmbH (DE) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096814-A1 | ALLELE-SPECIFIC AMPLIFICATION OF NUCLEIC ACIDS USING BLOCKING OLIGONUCLEOTIDES FOR WILD TYPE SUPPRESSION | ROCHE DIAGNOSTICS GMBH (DE) | 2016-06-23 | — | — | WO | claimed |
| US-20160177372-A1 | ALLELE-SPECIFIC AMPLIFICATION OF NUCLEIC ACIDS USING BLOCKING OLIGONUCLEOTIDES FOR WILD TYPE SUPPRESSION | ROCHE MOLECULAR SYSTEMS, INC. | 2016-06-23 | — | — | US | claimed |
| CN-105200097-A | IMPROVED ALLELE-SPECIFIC AMPLIFICATION | HOFFMANN LA ROCHE | 2015-12-30 | — | — | CN | claimed |
| EP-2510117-B1 | ALLELE-SPECIFIC AMPLIFICATION OF NUCLEIC ACIDS | ROCHE DIAGNOSTICS GMBH (DE) | 2014-12-10 | — | — | EP | claimed |
| WO-2011069677-A1 | ALLELE-SPECIFIC AMPLIFICATION OF NUCLEIC ACIDS | ROCHE DIAGNOSTICS GMBH (DE) | 2011-06-16 | — | — | WO | claimed |
| US-20100099110-A1 | Allele-Specific Amplification | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2010-04-22 | — | — | US | claimed |
| EP-1117838-B1 | A METHOD FOR ANALYZING POLYNUCLEOTIDES | VARIAGENICS INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1117838-A4 | A METHOD FOR ANALYZING POLYNUCLEOTIDES | VARIAGENICS INC (US) | 2007-05-02 | — | — | EP | claimed |
| CN-1463292-A | Method for analyzing polynucleotide | VARY GENIX CORP (US) | 2003-12-24 | — | — | CN | claimed |
| US-6566059-B1 | Method for analyzing polynucleotides | VARIAGENICS, INC. | 2003-05-20 | — | — | US | claimed |
| JP-2002525129-A | — | — | 2002-08-13 | — | — | JP | claimed |
| EP-1117838-A1 | A METHOD FOR ANALYZING POLYNUCLEOTIDES | Variagenics, Inc. (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018967-A1 | A METHOD FOR ANALYZING POLYNUCLEOTIDES | VARIAGENICS, INC. (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0625985-B1 | METHOD AND RING-OPENED PURINE COMPOUNDS FOR LABELING POLYNUCLEOTIDES | UNIV MIAMI (US) | 1997-06-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363172-A1 | 5'-CAP-TRINUCLEOTIDE- OR HIGHER OLIGONUCLEOTIDE COMPOUNDS AND THEIR USE IN STABILIZING RNA, EXPRESSING PROTEINS IN THERAPY | RNMT, RNGTT, NSUN3 | ADORA2B 2996/4885ADORA2A 1232/4885ADORA3 1937/4885 |
| US-20100099110-A1 | Allele-Specific Amplification | RNGTT, HLA-C, POLL | ADORA2B 482/4885ADORA2A 354/4885ADORA3 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.